



OPEN ACCESS

EDITED BY

Sebastian Kelle,
German Heart Center Berlin, Germany

REVIEWED BY

Satoshi Kodera,
The University of Tokyo, Japan
Zartasha Mustansar,
National University of Science and Technology,
Pakistan

*CORRESPONDENCE

Kenya Kusunose
✉ echo.cardio@gmail.com
🐦 @Ken_Cardiology

[†]These authors have contributed equally to this work

RECEIVED 27 October 2022

ACCEPTED 24 April 2023

PUBLISHED 19 May 2023

CITATION

Kusunose K, Hirata Y, Yamaguchi N, Kosaka Y, Tsuji T, Kotoku J and Sata M (2023) Deep learning approach for analyzing chest x-rays to predict cardiac events in heart failure. *Front. Cardiovasc. Med.* 10:1081628. doi: 10.3389/fcvm.2023.1081628

COPYRIGHT

© 2023 Kusunose, Hirata, Yamaguchi, Kosaka, Tsuji, Kotoku and Sata. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Deep learning approach for analyzing chest x-rays to predict cardiac events in heart failure

Kenya Kusunose^{1*†}, Yukina Hirata^{2†}, Natsumi Yamaguchi², Yoshitaka Kosaka¹, Takumasa Tsuji³, Jun'ichi Kotoku³ and Masataka Sata¹

¹Department of Cardiovascular Medicine, Tokushima University Hospital, Tokushima, Japan, ²Ultrasound Examination Center, Tokushima University Hospital, Tokushima, Japan, ³Department of Radiological Technology, Graduate School of Medical Care and Technology, Teikyo University, Tokyo, Japan

Background: A deep learning (DL) model based on a chest x-ray was reported to predict elevated pulmonary artery wedge pressure (PAWP) as heart failure (HF).

Objectives: The aim of this study was to (1) investigate the role of probability of elevated PAWP for the prediction of clinical outcomes in association with other parameters, and (2) to evaluate whether probability of elevated PAWP based on DL added prognostic information to other conventional clinical prognostic factors in HF.

Methods: We evaluated 192 patients hospitalized with HF. We used a previously developed AI model to predict HF and calculated probability of elevated PAWP. Readmission following HF and cardiac mortality were the primary endpoints.

Results: Probability of elevated PAWP was associated with diastolic function by echocardiography. During a median follow-up period of 58 months, 57 individuals either died or were readmitted. Probability of elevated PAWP appeared to be associated with worse clinical outcomes. After adjustment for readmission score and laboratory data in a Cox proportional-hazards model, probability of elevated PAWP at pre-discharge was associated with event free survival, independent of elevated left atrial pressure (LAP) based on echocardiographic guidelines ($p < 0.001$). In sequential Cox models, a model based on clinical data was improved by elevated LAP ($p = 0.005$), and increased further by probability of elevated PAWP ($p < 0.001$). In contrast, the addition of pulmonary congestion interpreted by a doctor did not statistically improve the ability of a model containing clinical variables (compared $p = 0.086$).

Conclusions: This study showed the potential of using a DL model on a chest x-ray to predict PAWP and its ability to add prognostic information to other conventional clinical prognostic factors in HF. The results may help to enhance the accuracy of prediction models used to evaluate the risk of clinical outcomes in HF, potentially resulting in more informed clinical decision-making and better care for patients.

KEYWORDS

heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, artificial intelligence, deep learning, chest x-ray

Introduction

Heart failure (HF) continues to be a significant socioeconomic issue and is one of the top causes of death from cardiovascular disease (CV) (1). Despite the development of current therapy, readmission rates for HF have remained high (2). The identification of hospitalized patients with a high risk of HF readmission is important for providing timely

interventions. Understanding the underlying etiology, severity, and prognosis of HF requires evaluation of CV imaging (3, 4). A standard chest x-ray (CXR) in patients with suspected HF has a certain clinical value in the diagnosis and management of HF (5, 6). However, the sensitivity and specificity of this imaging modality is relatively low (7, 8).

Recently, artificial intelligence (AI) including deep learning (DL) has been used to provide precise recognition of understated patterns in medical images (9, 10). We reported that a DL model based on CXR analysis predicted elevated pulmonary artery wedge pressure (PAWP) in patients who had undergone right heart catheterization (11). The probability of elevated PAWP may therefore be a potential tool for managing HF in the clinical setting. We hypothesize that a previously developed application of a CXR-based DL algorithm could also be used to predict re-hospitalized HF in patients with HF. The aims of the current study were (1) to investigate the potential of probability of elevated PAWP for the prediction of clinical outcomes in association with other parameters, and (2) to evaluate whether probability of elevated PAWP based on AI added prognostic information to other clinical prognostic factors in patients with HF.

Methods

Study population

A single-center, retrospective study was designed (Figure 1). Two hundred seventy-two patients who were first HF hospitalized were enrolled initially. The study's time frame was from January 2013 to December 2017. Patients with HF were defined as having a clear history of HF with typical symptoms


that were accompanied by signs including pulmonary congestion and BNP elevation (12). Exclusion criteria were post valve replacement, pacemaker implantation, active cancer, severe valvular disease and severe chronic obstructive pulmonary disease. Patients without clinical data at discharge were excluded. After these exclusions, 192 HF hospitalized patients were included in the final analysis. We divided this cohort into two groups: HF with reduced ejection fraction (HFrEF, $n = 99$) and HF with preserved EF (HFpEF, $n = 93$). Left ventricular ejection fraction (LVEF) less than 50% was designated as HFrEF, whereas LVEF greater than 50% was designated as HFpEF (13, 14). Patients collected to build the AI model were not included in this study.

Chest x-ray

The Radiology Department performed all chest radiographs. One attending cardiologist who had no prior knowledge of the patients' clinical information or hemodynamic status assessed the CXR images. A typical posteroanterior chest radiograph was used to measure the cardiothoracic ratio (CTR), which measures the size of the cardiac chambers. Consensus of two expert agreement of lung congestions on CXR images was used.

AI model for detection of PH

We used a previously developed AI model based on CXR analysis to predict elevated PAWP and then the continuous output of a classification network as a probability of elevated PAWP in the study cohort (11). The study involved examining



CXR data at admission and discharge. All patients underwent CXR within 24 h of admission and 48 h before discharge. The AUC of ResNet 50 for predicting elevated PAWP (mean PAWP >18 mmHg) was 0.77 in the study cohort (11). The batch size was set at 16, with the Adam optimizer used for training (15). The whole learning process was calculated by a graphics processing unit (Geforce RTX 2080 Ti 11 Gb, NVIDIA) using Ubuntu 18.04 and Chainer version 5.1.0. We performed gradient-weighted class activation mapping (Grad-CAM) to visualize how our model detected a PAWP >18 mmHg from a CXR of each patient (16).

Echocardiographic assessment

Echocardiography was performed using commercially available ultrasound machines. The echocardiographic data were obtained during the hospitalization according to the recommendations of the American Society of Echocardiography (17). Apical two- and four-chamber images were included. The biplane method of disks in two dimensions was used to calculate the volumes of the left atrium (LA) and LV. The LA volume index (LAVi) and LVEF were determined using these volumes. Based on 2016 recommendations, we implemented a decision tree using the mean E/e' ratio, tricuspid regurgitant: TR velocity, and LAVi to identify the existence of elevated LA pressure (LAP) (18). Three criteria are required to decide if there is raised LAP: E/e' ratio >14, LAVi > 34 ml/m², TR velocity >2.8 m/s.

Calculation of readmission risk scores

The Yale-CORE HF application [developed by Yale New Haven Health Services Corporation/Center for Outcomes Research and Evaluation (YNHHSC/CORE)] was used to determine the readmission risk for each patient (19). Readmission risk was calculated using 20 variables per patient, including demographic and historical variables abstracted from the medical record, admission physical examination variables, and laboratory and clinical variables (age, sex, in-hospital cardiac arrest, history of diabetes, previous HF, coronary artery disease, previous percutaneous coronary intervention, aortic stenosis, stroke, chronic obstructive pulmonary disease, prior diagnosis of dementia, systolic blood pressure, heart rate, respiratory rate, plasma sodium, creatinine, and glucose levels, blood urea nitrogen level, hematocrit, and LVEF). The risk scores could be calculated without any missing data.

Clinical outcomes

At Tokushima University Hospital, all patients received follow-up care, with clinical follow-up visits occurring at least every three months. After the follow-up echocardiography, the follow-up period began and terminated in May 2021. At Tokushima University Hospital or one of its affiliated hospitals, all the patients received

follow-up care. There was no patient lost to follow-up. The AI data had little influence on clinical management. The primary endpoint was cardiac death or readmission due to HF using predetermined criteria. HF readmission was defined as admission for a primary diagnosis of HF and CV death as passing away from a CV cause, such as a myocardial infarction, a cerebrovascular accident, or sudden cardiac death. Based on previously published reports (20, 21), we mainly used variables measured at pre-discharge to assess the prognostic values in the study.

Statistical analysis

Categorical data were expressed as an absolute number and percentages, whereas continuous data were expressed as mean standard deviation. Based on the likelihood of an elevated PAWP (>50%) being normal or abnormal, the patients were split into two groups. The Mann-Whitney U test or the unpaired Student's t test, as applicable, was used to compare continuous variables. Depending on the situation, the Fisher's exact test or the 2 test were used to compare categorical variables. The probability of elevated PAWP was used to divide the patients into two groups for Kaplan-Meier analysis, with survival compared using the log-rank test. A median value of Δ probability of elevated PAWP was used as the definition of improved probability of elevated PAWP. We used a Cox proportional-hazard model to determine the factors associated with survival. The variables selected were based on previous knowledge for the assessment of prognosis in patients with HF. To ascertain the incremental value of the probability of elevated PAWP over clinical data in relation to the main endpoint, sequential Cox models were built. The incremental prognostic value was defined as an increase in the global log-likelihood χ^2 of the model that was statistically significant. The assumption of proportional hazards was assessed by plotting the scaled Schoenfeld residuals for each independent variable against time to determine whether these correlations were nonsignificant. Time-dependent receiver operating characteristic (ROC) curves were used to calculate the C-statistic analyzed by the R package survival ROC. The DeLong method was used to compare the C-statistic. All statistical analyses were performed using SPSS 21.0 (SPSS, Chicago, IL, USA), MedCalc 19.5.6 (Mariakerke, Belgium), and R 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria). A *P* value <0.05 was considered statistically significant.

Results

Clinical backgrounds

Table 1 shows the baseline characteristics of the patients at discharge. A total of 192 hospitalized patients with HF (mean age 69 ± 14 years; 61% male) were divided into two groups: those with HFrEF and those with HFpEF. The patients were treated with an ACEi/ACE (65%), β -blocker (79%), or diuretics (73%). No significant difference was observed between the two groups

TABLE 1 Clinical characteristics.

	All (n = 192)	HFpEF (n = 93)	HFrEF (n = 99)	p value
Age (years)	69 ± 14	71 ± 14	68 ± 14	0.07
Male, n (%)	117 (61%)	46 (49%)	71 (72%)	0.002
BSA (m ²)	1.62 ± 0.23	1.58 ± 0.22	1.66 ± 0.22	0.02
Heart rate (beats/min)	86 ± 20	82 ± 20	89 ± 20	0.01
Systolic BP (mmHg)	126 ± 24	129 ± 26	122 ± 23	0.05
Diastolic BP (mmHg)	74 ± 17	72 ± 18	75 ± 16	0.16
Readmission for HF, n (%)	57 (30%)	30 (32%)	27 (27%)	0.45
Backgrounds				
Hypertension, n (%)	131 (68%)	69 (74%)	62 (63%)	0.09
Diabetes, n (%)	80 (42%)	37 (40%)	43 (43%)	0.61
Chronic atrial fibrillation, n (%)	35 (18%)	20 (22%)	15 (15%)	0.26
Ischemic cardiomyopathy, n (%)	43 (22%)	11 (12%)	32 (32%)	<0.001
Laboratory data				
Hb (g/dl)	12.1 ± 2.3	11.9 ± 2.4	12.2 ± 2.2	0.25
eGFR (ml/min/1.73 m ²)	50 ± 25	50 ± 26	50 ± 24	0.94
BNP (pg/ml)	228 (92, 471)	192 (62, 350)	291 (127, 531)	0.002
Chest x-ray on pre-discharge				
CTR	56 ± 7	55 ± 8	56 ± 7	0.17
Lung congestion, n (%)	53 (28%)	26 (26%)	27 (27%)	0.88
Echocardiographic parameters				
LVEF (%)	45 ± 15	59 ± 7	32 ± 7	–
LVEDVi (ml/m ²)	83 ± 32	64 ± 26	101 ± 25	<0.001
LAVi (ml/m ²)	51 ± 19	50 ± 19	52 ± 19	0.57
E/e' ratio	13.8 ± 8.3	13.4 ± 8.2	14.2 ± 8.4	0.49
TR-V (m/s)	2.48 ± 0.46	2.55 ± 0.44	2.40 ± 0.47	0.02
Elevated LAP (%)	102 (53%)	50 (54%)	52 (53%)	0.86
AI parameters				
Probability of elevated PAWP on admission (%)	76 (23, 95)	70 (10, 95)	84 (26, 96)	0.16
Probability of elevated PAWP on pre-discharge (%)	11 (2, 62)	7 (2, 64)	13 (2, 55)	0.91
ΔProbability of elevated PAWP (%)	26 (2, 68)	12 (1, 61)	36 (3, 77)	0.17

Data are presented as number of patients (percentage), mean ± SD or median (interquartile range).

BSA, body surface area; BP, blood pressure; HF, heart failure; ACEi/ARB, angiotensin-converting-enzyme inhibitor/angiotensin II receptor blocker; HB, hemoglobin; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVEDVi, left ventricular end-diastolic volume index; LAVi, left atrial volume index; E, early diastolic transmitral flow velocity; e', early diastolic mitral annular motion; TR-V, tricuspid regurgitant velocity; LAP, left atrial pressure.

for age, blood pressure, and comorbidities except for ischemic cardiomyopathy. The patients with HFrEF included a higher number of males, a higher use of β -blockers, increased brain natriuretic peptide (BNP) levels, and a larger LV size. Interestingly, there was no difference in CXR profiles including CTR, lung congestion, probability of elevated PAWP on admission and pre-discharge between the two groups.

The characteristics and echocardiographic parameters of the two groups with and without an abnormal elevated PAWP at

pre-discharge are shown in **Table 2**. In this analysis, LAVi ($p = 0.03$), TR velocity ($p = 0.01$), and the presence of elevated LAP ($p = 0.008$) were associated with an abnormal probability of elevated PAWP. This result indicated probability of elevated PAWP was linked to left ventricular diastolic function. In patients with a normal probability of elevated PAWP on pre-discharge, the median probability of elevated PAWP on admission was 69%, while change in probability of elevated PAWP from admission to pre-discharge (Δ probability of elevated PAWP) was 53%. On the other hand, in patients with an abnormal probability of elevated PAWP on pre-discharge, the median probability of elevated PAWP on admission was high (94%). The status of lung congestion in patients with a higher probability of elevated PAWP may not have been reduced at pre-discharge. Based on expert CXR assessments, lung congestion is more frequent in patients with an abnormal probability of elevated PAWP.

Cardiac mortality and readmission to HF

During a median follow-up period of 58 months (range, 11–80 months), 57 patients (30%) reached the primary endpoint (CV death, $n = 13$, or readmission due to HF, $n = 44$). During the follow-up period, no patient passed away from anything other than CV disease. **Figure 2A** shows the time to the primary endpoint. Probability of elevated PAWP appeared to be associated with worse clinical outcomes in both the HFpEF ($p < 0.001$) and HFrEF ($p = 0.003$) cohorts. **Figure 2B** shows the event-free survival of patients stratified according to the presence of an elevated LAP and abnormal probability of elevated PAWP (probability of elevated PAWP >50%). Patients with an elevated LAP and abnormal probability of elevated PAWP had significantly shorter event-free survival than those without these abnormalities ($p < 0.001$). In addition, **Figure 2C** shows the event-free survival of patients stratified according to improved or not improved probability of elevated PAWP (Δ probability of elevated PAWP, cut-off value: 26%). Patients without an improved probability of elevated PAWP had significantly shorter event-free survival than those with an improved probability of elevated PAWP ($p = 0.03$).

We used univariate and multivariate Cox proportional-hazard regression analysis to identify the variables connected to the main outcome. In the univariate model, the Yale-CPRE HF score, estimated glomerular filtration rate (eGFR), log BNP, LAVi, E/e' ratio, TR-V, and elevated LAP as defined by the 2016 recommendations were linked to the primary endpoint (**Table 3**). The probability of elevated PAWP at admission was not related to the primary endpoint. Importantly, probability of elevated PAWP at pre-discharge (per 1SD) was related significantly with the primary outcomes (hazard ratio: 1.46, 95% CI: 1.23–1.72, $p < 0.001$). In addition, Δ probability of elevated PAWP from admission to pre-discharge was also associated with clinical outcomes. Pulmonary congestion by expert assessment was weakly associated with clinical outcomes ($p = 0.049$).

TABLE 2 Clinical and echocardiographic parameters between normal and abnormal probability of elevated PAWP on pre-discharge.

x-ray group	Normal probability of elevated PAWP on pre-discharge	Abnormal probability of elevated PAWP on pre-discharge	<i>p</i> value
Number	134	58	
AI parameters			
Probability of elevated PAWP on pre-discharge (%)	3 (1, 13)	81 (65, 95)	–
Probability of elevated PAWP on admission (%)	69 (14, 92)	94 (67, 99)	<0.001
ΔProbability of elevated PAWP (%)	53 (6, 87)	9 (0, 44)	<0.001
Characteristics			
Age (years)	70 ± 14	69 ± 14	0.79
Male, %	38 (66)	82 (59)	0.39
Heart rate (beats/min)	86 ± 21	86 ± 19	0.89
Systolic BP (mmHg)	125 ± 22	128 ± 29	0.54
Yale-CORE HF score	22 ± 4	23 ± 4	0.26
Medications			
ACEi or ARB, <i>n</i> (%)	87 (65)	37 (64)	0.88
β-blocker, <i>n</i> (%)	107 (80)	45 (78)	0.73
Diuretics, <i>n</i> (%)	96 (72)	44 (76)	0.54
Laboratory data			
eGFR (ml/min/1.73 m ²)	52 ± 26	46 ± 22	0.12
BNP (pg/ml)	236 (91, 471)	210 (107, 464)	0.55
Chest x-ray on pre-discharge			
CTR	55 ± 8	58 ± 7	0.02
Lung congestion, <i>n</i> (%)	25 (19)	28 (48)	0.001
Echocardiographic parameters			
LVEF (%)	45 ± 15	46 ± 16	0.76
LVEDVi (ml/m ²)	84 ± 32	83 ± 30	0.84
LAVi (ml/m ²)	49 ± 18	56 ± 21	0.03
<i>E/e'</i> ratio	13.1 ± 7.4	15.3 ± 9.9	0.13
TR-V (m/s)	2.41 ± 0.41	2.61 ± 0.54	0.01
Elevated LAP (%)	63 (47%)	39 (67%)	0.008

See abbreviations as in Table 1.

In the multivariate analysis (Table 4), both elevated LAP and probability of elevated PAWP based on the AI algorithm were significant predictors for the primary outcomes after adjustment for the Yale-CORE HF score, log BNP, and eGFR. Furthermore, the Δprobability of elevated PAWP was also a predictor for the primary endpoint after adjustment for these variables.

Figure 3 shows the added benefit of AI parameters for predicting the primary outcomes. The addition of echocardiographic assessment (elevated LAP) and probability of elevated PAWP significantly improved the ability of a model containing the Yale-CORE HF score, eGFR, and log BNP (model 1), Yale-CORE HF score, $\chi^2 = 4.4$ (model 2), plus eGFR and log BNP, $\chi^2 = 16.8$, $p = 0.001$ (model 3), plus elevated LAP, $\chi^2 = 24.4$, $p = 0.005$, plus probability of elevated PAWP on pre-discharge, $\chi^2 = 41.1$, $p < 0.001$. In contrast, the addition of pulmonary congestion interpreted by a doctor did not statistically improve the ability of a model containing the Yale-CORE HF score, eGFR, log BNP, and elevated LAP (model 3 plus pulmonary congestion, from $\chi^2 = 24.4$ to $\chi^2 = 27.5$, compared $p = 0.086$).

For the Cox model based on lung congestion by expert assessment, the Harrell C concordance statistic was calculated as 0.55 (95% CI: 0.49–0.61). The Harrell C concordance statistic was calculated as 0.72 (95% CI: 0.65–0.78) for the Cox model

based on the Yale-CORE HF score, eGFR, pro BNP, and elevated LAP. When probability of elevated PAWP was added to the model, the C-statistic improved significantly to 0.78 (95% CI: 0.71–0.84, $p = 0.039$ for the comparison).

Assessment of Grad-CAM

We analyzed the images to determine where AI was focused to help explain the AI assessment (Figure 4). Grad-CAM demonstrated that in our situations, whether a patient had primary events or not, our model focused on the heart region. The proposed AI model may thus offer fresh perspectives to accurately identify differences in CXR images in the future large dataset.

Discussion

The objective of this study was to assess the clinical meanings of probability of elevated PAWP based on an AI algorithm, as an association between probability of elevated PAWP and CV events. The study provided several insights into the interpretation of probability of elevated PAWP: (1) probability of elevated




FIGURE 2 Kaplan-Meier analysis of event-free survival. (A) According to the presence or absence of abnormal probability of elevated PAWP in HFpEF and HFrEF, we divided patients into 2 groups. (B) According to the presence of an elevated left atrial pressure based on echocardiography and probability of elevated PAWP based on artificial intelligence, we divided patients into 4 groups. (C) According to the presence or absence of abnormal probability of elevated PAWP for improved and not-improved probability of elevated PAWP.

PAWP was related to left ventricular diastolic function; (2) patients with an abnormal probability of elevated PAWP had a significantly higher event rate compared to patients with a normal probability of elevated PAWP; (3) the association between probability of elevated PAWP and the primary endpoints remained significant after

adjustment for HF risk score, laboratory data, and echocardiographic data. Interestingly, Lung congestion assessed by one attending cardiologist was only weakly associated with outcomes. This information might provide insights into the clinical utility of medical imaging based on an AI algorithm in patients with HF beyond assessments by experts. Our findings suggest that the likelihood of elevated PAWP may be helpful for clinical evaluation and follow-up during the ideal period of medical treatment.

Findings on probability of elevated PAWP in chest x-rays

The association between classical radiographic features of HF in CXR images and physiological hemodynamic parameters has been described previously (22, 23). Cephalization of pulmonary venous blood flow occurs with redistribution of pulmonary blood flow and typically when the PAWP is >10–15 mmHg. Interstitial edema characterized by Kerley B lines is thought to result when the PAWP is >20 mmHg due to thickening of the interlobular septa. Alveolar edema is present when the PAWP exceeds 25 mmHg. However, these radiographic changes are not always present and sometimes may only be partially present, or indeed absent, even in cases of clinically significant HF. An increased cardiothoracic ratio is more common and more sensitive; however, it is less specific (24). Although these important findings may be present in CXR images, diagnostic limitations of the clinical and simple radiographic parameters are also observed in the clinical setting. In this study, the assessment of CXR by experts was not so strongly associated with outcomes.

Previously, we trained the AI model to detect an elevated PAWP >18 mmHg (11). Theoretically, an elevated probability of elevated PAWP based on AI can be associated with residual pulmonary congestion and cardiac enlargement. Based on our results, abnormal probability of elevated PAWP is associated with larger LA volumes, relatively higher E/e' as a marker of LV filling pressure, higher tricuspid valve regurgitant velocity, and the proportion of elevated LAP (Table 2). Interestingly, the LV systolic function was not significantly associated with probability of elevated PAWP. Therefore, this index appears to be a sensitive marker of LV diastolic parameters in the clinical setting. Further studies are designed to clarify the detail of the hemodynamic mechanism for probability of elevated PAWP using simultaneous recordings of cardiac pressures measured using invasive catheters.

Probability of elevated PAWP and outcomes

In univariate analysis, the Yale-CORE HF score, BNP level, renal function, and elevated LAP measured by echocardiography were associated with clinical events. The parameters are used to predict CV events, including HF rehospitalization. After adjustment for these known factors, the probability of elevated PAWP based on an AI algorithm was associated with the primary outcome. There is a possible explanation for the

association between probability of elevated PAWP and worse clinical outcomes. Based on our results of congestive CXR images, probability of elevated PAWP appears to reflect elevated LA pressures. Several studies have shown that an elevated PAWP was associated significantly with CV events (25, 26). These associations possibly explain the association between probability of elevated PAWP and clinical events. More importantly, the changes in probability of elevated PAWP between admission and pre-discharge were also associated with clinical events. A recent publication from PARADIGM-HF showed that signs of

persistent congestion observed in physical examinations provided significant independent prognostic value even beyond symptoms and the levels of natriuretic peptides (27). When patients who do not respond satisfactorily to HF therapy are confirmed by a pre-discharge CXR, further administration of diuretics or other intensive treatment for HF may be considered in the clinical setting. We found that probability of elevated PAWP at admission was not associated with subsequent clinical events and therefore concluded that pre-discharge assessment should be recommended for hospitalized HF patients in order to provide more information about their status.

TABLE 3 Univariate associations of primary outcomes in hospitalized heart failure.

	HR (95%CI)	p value
Characteristics		
Age (years)	1.01 (0.99–1.03)	0.30
Male	0.97 (0.57–1.66)	0.92
Heart rate	0.99 (0.98–1.01)	0.25
Systolic BP	1.00 (0.99–1.01)	0.60
Yale-CORE HF score	1.08 (1.01–1.15)	0.03
Medications		
ACEi or ARB	0.86 (0.50–1.48)	0.59
β-blocker	0.80 (0.43–1.49)	0.48
Diuretics	1.55 (0.80–2.99)	0.19
Laboratory data		
eGFR (ml/min/1.73 m ²)	0.98 (0.97–0.99)	0.003
Log BNP	2.66 (1.53–4.65)	0.001
Chest x-ray on pre-discharge		
CTR	0.37 (0.01–13.08)	0.58
Lung congestion	1.73 (1.00–2.98)	0.049
Echocardiographic parameters		
LVEF (%)	0.99 (0.98–1.01)	0.41
LVEDVi (ml/m ²)	1.00 (0.99–1.01)	0.57
LAVi (ml/m ²)	1.02 (1.00–1.03)	0.02
E/e' ratio	1.04 (1.02–1.07)	0.001
TR-V (m/s)	1.85 (1.09–3.13)	0.02
Elevated LAP (%)	2.87 (1.59–5.18)	<0.001
AI parameters		
Probability of elevated PAWP on admission (per 1SD)	1.15 (0.94–1.41)	0.17
Probability of elevated PAWP on pre-discharge (per 1SD)	1.46 (1.23–1.72)	<0.001
ΔProbability of elevated PAWP (per 1SD)	0.71 (0.55–0.92)	0.01

HR, hazard ratio; CI, confidence interval; other abbreviations as in Table 1.

Artificial intelligence in the clinical setting

At present, many AI imaging studies estimate diagnostic accuracy using sensitivity and specificity (28), while there is limited data available to assess clinical outcomes. To help progress the study of AI in medical images it is necessary to assess the effects on clinically meaningful endpoints to improve applicability and allow effective deployment into clinical practice (29). In addition, it is essential to AI research to consistently use out-of-sample external validation and well-defined patient cohorts to augment the quality and interpretability of AI. In the present study we investigated an independent cohort with a previously published application of an AI model for probability of elevated PAWP used to provide prognostic value in patients with HF. We hope that AI imaging may be used in the near future not only for diagnostic accuracy but also for clinical utility (e.g., prediction of prognosis).

Clinical utility of probability of elevated PAWP

The results of this study suggest that the probability of elevated PAWP based on AI algorithm provides incremental value to known parameters including clinical data, laboratory data and echocardiography. To our knowledge, this study is the first to examine the clinical efficacy of AI algorithms in HF patients and their relationship to cardiac events during follow-up. The probability of elevated PAWP will be significant in that it is simple, reproducible, measurable at almost all institutes and

TABLE 4 Multivariate associations of primary outcomes in hospitalized heart failure.

	Model 1 (χ ² : 24.4)			Model 2 (χ ² : 31.4)			Model 3 (χ ² : 41.1)		
	HR	95%CI	p value	HR	95%CI	p value	HR	95%CI	p value
Clinical parameters									
Yale-CORE HF score	1.01	0.93–1.09	0.86	1.02	0.94–1.10	0.70	1.01	0.93–1.09	0.86
Log BNP	1.90	1.03–3.52	0.04	1.99	1.07–3.70	0.03	1.97	1.11–3.50	0.02
eGFR	0.99	0.97–1.00	0.08	0.99	0.98–1.00	0.16	0.99	0.98–1.01	0.23
Echocardiography									
Elevated LAP	2.29	1.24–4.21	0.008	2.19	1.19–4.03	0.012	1.97	1.07–3.62	0.03
ΔProbability of elevated PAWP (per 1SD)				0.73	0.57–0.95	0.017			
Probability of elevated PAWP on pre-discharge (Per 1SD)							1.39	1.17–1.65	<0.001

HR, hazard ratio; CI, confidence interval; other abbreviations as in Table 1.




FIGURE 3 Incremental value of echocardiographic parameters. These figures illustrate the global χ^2 of sequential Cox models that incorporated several clinical parameters. eGFR, estimate glomerular filtration rate; BNP, brain natriuretic peptide; LAP, left atrial pressure; HF, heart failure; HR, hazard ratio.




FIGURE 4 Representative cases with Grad-CAM images. Chest x-rays were visualized using Grad-CAM, with the yellow and red areas showing regions that the deep learning model considered important for probability of elevated PAWP.

reflects prognostic power in heart failure. Model performance on prediction is significant at pre-discharge and poor at admission. The results are consistent with the finding that rehospitalization is less likely if congestion is well controlled (30). This model may play an important role as a guide for treatment of residual congestion in HF. Our data suggested that the changes in probability of elevated PAWP on x-rays during hospitalization may reflect the course of treatment for heart failure. We expect that it can be modeled and validated with multicenter data and used in clinical settings in the future.

Limitations

The present study has several limitations. First, this was a single tertiary heart centers study with a small sample size in Japan. Therefore, the generalizability of the study findings was limited. On the other hand, we believed that the single-center study would have less biases than a study with a larger sample size, such as those caused by disparities in treatment effectiveness or a wide range of etiologies. Because there were so few events in the sample, there is a chance that the model will be overfit. Second, the cut-off value for abnormal probability of elevated PAWP (50%) was determined by our previous paper, thus, the accurate cut-off values may not be well organized in the different cohort. The validity and reliability of AI algorithms should improve in the near future with advances in machine learning and augmented data set. The study period was from 2013 to 2017. Some HF pharmacotherapies such as SGLT-2 inhibitors were not available routinely. Because this study was designed to evaluate the performance of AI for risk stratification of HF, it was not possible to assess this AI model in patients without HF. These limitations suggest that the current study should be considered as hypothesis-generating. Additional research is required to quantify the likelihood of elevated PAWP more fully in a multi-center large cohort that includes healthy populations.

Conclusions

CXR assessment using the AI model may provide important incremental prognostic value for predicting readmission and cardiac mortality risk assessment in patients with HF compared with doctor-interpreted pulmonary congestion. The results may help to enhance the accuracy of prediction models used to evaluate the risk of clinical outcomes in HF, potentially resulting in more informed clinical decision-making and better care for patients.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The present study was approved by the Institutional Review Board of the Tokushima University Hospital. Reference number: 3217-4. The ethics committee waived the requirement of written informed consent for participation.

Author contributions

Design of the work: KK; conduct of the work and data acquisition: YH, NY, and YK; data analysis and interpretation: TT and JK; drafting the work: KK and YH; reviewing the work and providing input: all authors. All authors contributed to the article and approved the submitted version.

Funding

This work was partially supported by JSPS KAKENHI grants (number 23K07509 to KK and 21K12706 to YH) and a grant from the Japan Agency for Medical Research and Development (AMED, JP22uk1024007 to KK).

Acknowledgments

The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics—2022 update: a report from the American heart association. *Circulation*. (2022) 145(8):e153–639. doi: 10.1161/CIR.0000000000001052
2. Khera R, Wang Y, Nasir K, Lin Z, Krumholz HM. Evaluation of 30-day hospital readmission and mortality rates using regression-discontinuity framework. *J Am Coll Cardiol*. (2019) 74(2):219–34. doi: 10.1016/j.jacc.2019.04.060
3. Lassen MCH, Olsen FJ, Skaarup KG, Tolstrup K, Qasim AN, Gislason G, et al. The clinical application of the ratio of transmitral early filling velocity to early diastolic strain rate: a systematic review and meta-analysis. *J Echocardiogr*. (2020) 18(2):94–104. doi: 10.1007/s12574-020-00466-w
4. Tanaka H. Utility of strain imaging in conjunction with heart failure stage classification for heart failure patient management. *J Echocardiogr*. (2019) 17(1):17–24. doi: 10.1007/s12574-018-0408-2
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. *Eur Heart J*. (2012) 33(14):1787–847. doi: 10.1093/eurheartj/ehs104
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). developed with the special contribution of the heart failure association (HFA) of the ESC. *Eur J Heart Fail*. (2016) 18(8):891–975. doi: 10.1002/ehf.592
7. Costanzo WE, Fein SA. The role of the chest x-ray in the evaluation of chronic severe heart failure: things are not always as they appear. *Clin Cardiol*. (1988) 11(7):486–8. doi: 10.1002/clc.4960110710
8. Jogi J, Al-Mashat M, Radegran G, Bajc M, Arheden H. Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization. *ESC Heart Fail*. (2018) 5(5):902–10. doi: 10.1002/ehf2.12317
9. Kusunose K, Abe T, Haga A, Fukuda D, Yamada H, Harada M, et al. A deep learning approach for assessment of regional wall motion abnormality from echocardiographic images. *JACC Cardiovasc Imaging*. (2020) 13:374–81. doi: 10.1016/j.jcmg.2019.02.024
10. Kusunose K, Haga A, Abe T, Sata M. Utilization of artificial intelligence in echocardiography. *Circ J*. (2019) 83(8):1623–9. doi: 10.1253/circj.CJ-19-0420
11. Hirata Y, Kusunose K, Tsuji T, Fujimori K, Kotoku JI, Sata M. Deep learning for detection of elevated pulmonary artery wedge pressure using standard chest x-ray. *Can J Cardiol*. (2021) 37:1198–206. doi: 10.1016/j.cjca.2021.02.007
12. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. (2016) 37:2129–200. doi: 10.1093/eurheartj/ehw128
13. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure- digest version. *Circ J*. (2019) 83(10):2084–184. doi: 10.1253/circj.CJ-19-0342
14. Bozkurt B, Coats A, Tsutsui H. A report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure consensus conference. *Eur J Heart Fail*. (2021) 23:352–80. doi: 10.1002/ehf.2115
15. Kingma DP, Ba J. *Adam: A method for stochastic optimization*. arXiv preprint arXiv:1412.6980. (2014).
16. Selvaraju RR, Cogswell M, Das A, Vedantam R, Parikh D, Batra D. *Grad-CAM: visual explanations from deep networks via gradient-based localization*. *Proceedings of the IEEE international conference on computer vision*. (2017). p. 618–26. doi: 10.1109/ICCV.2017.74
17. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography. *J Am Soc Echocardiogr*. (2019) 32(1):1–64. doi: 10.1016/j.echo.2018.06.004
18. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. *J Am Soc Echocardiogr*. (2016) 29(4):277–314. doi: 10.1016/j.echo.2016.01.011
19. Keenan PS, Normand SL, Lin Z, Drye EE, Bhat KR, Ross JS, et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. *Circ Cardiovasc Qual Outcomes*. (2008) 1(1):29–37. doi: 10.1161/CIRCOUTCOMES.108.802686
20. De Sousa Bispo J, Azevedo P, Freitas P, Marques N, Reis C, Horta E, et al. Mechanical dispersion as a powerful echocardiographic predictor of outcomes after myocardial infarction. *Eur Heart J*. (2020) 41(Supplement_2):ehaa946.0126. doi: 10.1093/ehjci/ehaa946.0126
21. Kokalj N, Kozak M, Jug B. Post-acute pre-discharge echocardiography in the long-term prognostic assessment of pulmonary thromboembolism. *Sci Rep*. (2021) 11(1):1–7. doi: 10.1038/s41598-021-82038-1
22. Hublitz UF, Shapiro JH. The radiology of pulmonary edema: four decades of observations, clinical correlation, and studies of the underlying pathophysiology. *CRC Crit Rev Clin Radiol Nucl Med*. (1974) 5:389–422. doi: 10.1161/CIRCOUTCOMES.108.802686
23. Mahdhyoon H, Klein R, Eyley W, Lakier JB, Chakko S, Gheorghide M. Radiographic pulmonary congestion in end-stage congestive heart failure. *Am J Cardiol*. (1989) 63(9):625–7. doi: 10.1016/0002-9149(89)90912-0
24. Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. *Eur J Heart Fail*. (2010) 12(11):1253–60. doi: 10.1093/eurjhf/hfq133
25. Eisman AS, Shah RV, Dhakal BP, Pappagianopoulos PP, Wooster L, Bailey C, et al. Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. *Circ Heart Fail*. (2018) 11(5):e004750. doi: 10.1161/CIRCHEARTFAILURE.117.004750
26. Arase M, Kusunose K, Morita S, Yamaguchi N, Hirata Y, Nishio S, et al. Cardiac reserve by 6-minute walk stress echocardiography in systemic sclerosis. *Open Heart*. (2021) 8(1):e001559. doi: 10.1136/openhrt-2020-001559
27. Selvaraj S, Claggett B, Pozzi A, McMurray JJ, Jhund PS, Packer M, et al. Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF. *Circulation*. (2019) 140(17):1369–79. doi: 10.1161/CIRCULATIONAHA.119.039920
28. Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, et al. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. *Lancet Digit Health*. (2019) 1(6):e271–297. doi: 10.1016/S2589-7500(19)30123-2
29. Oren O, Gersh BJ, Bhatt DL. Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. *Lancet Digit Health*. (2020) 2(9):e486–488. doi: 10.1016/S2589-7500(20)30160-6
30. Kobayashi M, Watanabe M, Coiro S, Bercker M, Paku Y, Iwasaki Y, et al. Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. *Int J Cardiol*. (2019) 289:91–8. doi: 10.1016/j.ijcard.2019.01.091